{"mainPropery":{"diseaseId":1033,"diseaseName":"X-linked agammaglobulinemia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/1033/x-linked-agammaglobulinemia","synonyms":["Bruton type agammaglobulinemia","Bruton's agammaglobulinemia","XLA","Agammaglobulinemia, BTK","Agammaglobulinemia, Bruton tyrosine kinase","BTK-deficiency"],"synonyms-with-source":[{"name":"Bruton type agammaglobulinemia"},{"name":"Bruton's agammaglobulinemia"},{"name":"XLA"},{"name":"Agammaglobulinemia, BTK"},{"name":"Agammaglobulinemia, Bruton tyrosine kinase"},{"name":"BTK-deficiency"}],"identifiers":[{"identifierType":"OMIM","identifierId":"300755"},{"identifierType":"ORPHANET","identifierId":"47"},{"identifierType":"UMLS","identifierId":"C0221026"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":13,"diseaseTypeName":"Immune System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":151,"resourceName":"Jeffrey Modell Foundation","abbreviation":"JMF","address1":"780 Third Ave","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10017","country":"United States","phone":"","tty":"","tollFree":"","fax":"212-764-4180","email":"info@jmfworld.org","url":"http://www.info4pi.org/","freeText":"JMF is a global patient organization devoted to early and precise diagnosis, meaningful treatments, and ultimately, cures - through clinical and basic research, physician education, patient support, advocacy, public awareness and newborn screening."},{"resourceID":152,"resourceName":"International Patient Organization for Primary Immunodeficiencies","abbreviation":"IPOPI","address1":"Rock Bottom, Trerieve","address2":"Downderry","address3":"PL11 3LY","address4":"","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"44-01503-250-668/961","tty":"","tollFree":"","fax":"","email":"Info@ipopi.org","url":"https://ipopi.org","freeText":""},{"resourceID":161,"resourceName":"Immune Deficiency Foundation","abbreviation":"","address1":"110 West Road, Suite 300","address2":"","address3":"","address4":"","address5":"","city":"Towson","state":"MD","zip":"21204","country":"United States","phone":"","tty":"","tollFree":"1-800-296-4433","fax":"+1-410-321-9165","email":"https://www.primaryimmune.org/services/ask-idf/","url":"https://www.primaryimmune.org/","freeText":""},{"resourceID":875,"resourceName":"Immune Deficiencies Foundation Australia","abbreviation":"","address1":"PO Box 969","address2":"Penrith NSW 2751","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Australia","phone":"800-100-198","tty":"","tollFree":"","fax":"","email":"info@idfa.org.au","url":"http://www.idfa.org.au/"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/300755' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=%28X-linked[Title]+AND+agammaglobulinemia[Title]%29+AND+%28hasabstract[text]+AND+%222003%2F01%2F30%22[PDat]+%3A+%222008%2F01%2F28%22[PDat]%29&WebEnv=0qM2NR13MHd3S32n8UwZLZxQn4zIn7waCypK6AJdziOKAVTQn03q8mYHYALlvxF_BPBqxC9JE1607-%40255F1BD7719152F0_0165SID&WebEnvRq=1' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss X-linked agammaglobulinemia. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22X-linked+agammaglobulinemia%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to X-linked agammaglobulinemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/x-linked-agammaglobulinemia' target='_blank'>Genetics Home Reference (GHR)</a> contains information on X-linked agammaglobulinemia. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0221026' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001307.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://www.emedicine.com/ped/topic294.htm' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=47' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1453/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merckmanuals.com/home/sec16/ch184/ch184m.html' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:300755' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with X-linked agammaglobulinemia. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;X-linked agammaglobulinemia:<br />\r\n<a href='https://usidnet.org/about-the-registry/patient-participation/' target='_blank'>United States Immunodeficiency Network (USIDENT) Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":4374,"questionText":"What is X-linked agammaglobulinemia?","answerText":"<strong>X-linked agammaglobulinema</strong> is a <a href=\"http://www.mayoclinic.org/diseases-conditions/primary-immunodeficiency/basics/definition/con-20031958\" target=\"_blank\">primary immunodeficiency</a> characterized by very low levels of immunoglobulins (proteins made by the immune system to help fight infections). People affected by this condition generally begin developing frequent and recurrent bacterial infections from about 6 months of age. Commonly diagnosed infections include lung infections (pneumonia and bronchitis), middle ear infections, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001010.htm\" target=\"_blank\">conjunctivitis</a>, sinus infections, various skin infections, and infections that are associated with chronic diarrhea.[11269][11270][11271] X-linked agammaglobulinemia is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"https://ghr.nlm.nih.gov/gene/BTK\" target=\"_blank\">BTK</a></em> gene and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002051.htm\" target=\"_blank\">X-linked recessive</a> manner.[11270][11271] Treatment aims to boost the immune system, which may be accomplished by administering immunoglobulins through a vein (IVIG) or subcutaneously (SCIG). Frequent infections are generally treated with antibiotics.[11269][11270]","dateModified":"2016-04-14T00:00:00"},"basicQuestions":[{"questionId":4375,"questionText":"What are the signs and symptoms of X-linked agammaglobulinemia?","answerText":"Affected infants are usually healthy for the first few months of life until they begin to develop recurrent <a href=\"http://www.nlm.nih.gov/medlineplus/bacterialinfections.html\" target=_blank>bacterial infections</a>. The most common bacterial infections are <a href=\"http://www.nlm.nih.gov/medlineplus/earinfections.html\" target=_blank>ear infections</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/pneumonia.html\" target=_blank>pneumonia</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/pinkeye.html\" target=_blank>pink eye</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000647.htm\" target=_blank>sinus infections</a>, and infections that cause chronic <a href=\"http://www.nlm.nih.gov/medlineplus/earinfections.html\" target=_blank>diarrhea</a>. These bacterial infections can be severe and&nbsp;life-threatening.&nbsp;Most affected individuals are not vulnerable to infections caused by <a href=\"http://www.nlm.nih.gov/medlineplus/viralinfections.html\" target=_blank>viruses</a>.<em> </em>Infections can usually be prevented with proper treatment.[3326]","dateModified":"2011-04-20T16:54:00","resourceClassificationName":"Symptoms","references":[{"referenceId":3326,"authors":"","articleTitle":"X-linked agammaglobulinemia","bookWebsiteJournalTitle":"Genetics Home Reference","date":"September 2008","url":"http://ghr.nlm.nih.gov/condition/x-linked-agammaglobulinemia","dateAccessed":"2011-04-20T00:00:00"}]},{"questionId":5033,"questionText":"How might X-linked agammaglobulinemia be treated?","answerText":"Managing X-linked agammaglobulinemia (XLA) mainly consists of preventing infections and treating infections aggressively when they do&nbsp;occur. Sudden&nbsp;infections in individuals with XLA&nbsp;are&nbsp;usually treated with antibiotics that are taken for at least twice as long as taken in healthy individuals. Preventing bacterial infections is very important for people with XLA. Gammaglobulin (a type of protein in the blood that contains antibodies to prevent or fight infections)&nbsp;is the main treatment for people with XLA. In the past, most&nbsp;people received&nbsp;this by intravenous (IV) infusion every two to four weeks. However, in the last few years, an increasing number of people have been receiving it by weekly <a href=\"http://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf\" target=_blank>subcutaneous injections</a>. The choice of whether to receive it intravenously or by injection&nbsp;may just depend on what is most convenient for the doctor and/or patient. Sometimes,&nbsp;people with XLA have a reaction to gammaglobulin, which may include&nbsp;headaches, chills, backache, or nausea. These reactions are more likely to occur when they have a viral infection or when the brand of gammaglobulin has been changed. Some centers use chronic prophylactic antibiotics (continuous use of antibiotics) to prevent bacterial infections.[4038]<br><br>Aggressive use of antibiotics lower the chance of <a href=\"http://www.mayoclinic.com/health/chronic-sinusitis/DS00232\" target=_blank>chronic sinusitis </a>and lung disease, which are common complications in individuals with XLA. Early diagnosis and treatment of bowel infections may decrease the risk of <a href=\"http://womenshealth.gov/publications/our-publications/fact-sheet/inflammatory-bowel-disease.cfm\" target=_blank>inflammatory bowel disease </a>(IBD). Furthermore,&nbsp;children with XLA should not be given live viral vaccines. For example, they should&nbsp;be given inactivated polio vaccine (IPV) rather than the oral polio vaccine. The siblings of children with XLA should also be given inactivated polio vaccine (IPV) rather than oral polio vaccine in order to avoid infecting their affected sibling with live virus.[4038]","dateModified":"2011-08-03T11:46:00","resourceClassificationName":"Treatment","references":[{"referenceId":4038,"authors":"Mary Ellen Conley, Vanessa C Howard","articleTitle":"X-Linked Agammaglobulinemia","bookWebsiteJournalTitle":"GeneReviews","date":"July 30, 2009","url":"http://www.ncbi.nlm.nih.gov/books/NBK1453/","dateAccessed":"2011-08-03T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":31785,"abbreviatedInquiry":"My child was diagnosed with X-linked agammaglobulinemia in 2008. He as been on antibiotics but now they are no longer effective, and in our country we don't have intravenous immunoglobulin (IVIG). What should&nbsp;I do to keep my child?","caseQuestions":[{"questionId":5033,"questionText":"How might X-linked agammaglobulinemia be treated?","answerText":"Managing X-linked agammaglobulinemia (XLA) mainly consists of preventing infections and treating infections aggressively when they do&nbsp;occur. Sudden&nbsp;infections in individuals with XLA&nbsp;are&nbsp;usually treated with antibiotics that are taken for at least twice as long as taken in healthy individuals. Preventing bacterial infections is very important for people with XLA. Gammaglobulin (a type of protein in the blood that contains antibodies to prevent or fight infections)&nbsp;is the main treatment for people with XLA. In the past, most&nbsp;people received&nbsp;this by intravenous (IV) infusion every two to four weeks. However, in the last few years, an increasing number of people have been receiving it by weekly <a href=\"http://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf\" target=_blank>subcutaneous injections</a>. The choice of whether to receive it intravenously or by injection&nbsp;may just depend on what is most convenient for the doctor and/or patient. Sometimes,&nbsp;people with XLA have a reaction to gammaglobulin, which may include&nbsp;headaches, chills, backache, or nausea. These reactions are more likely to occur when they have a viral infection or when the brand of gammaglobulin has been changed. Some centers use chronic prophylactic antibiotics (continuous use of antibiotics) to prevent bacterial infections.[4038]<br><br>Aggressive use of antibiotics lower the chance of <a href=\"http://www.mayoclinic.com/health/chronic-sinusitis/DS00232\" target=_blank>chronic sinusitis </a>and lung disease, which are common complications in individuals with XLA. Early diagnosis and treatment of bowel infections may decrease the risk of <a href=\"http://womenshealth.gov/publications/our-publications/fact-sheet/inflammatory-bowel-disease.cfm\" target=_blank>inflammatory bowel disease </a>(IBD). Furthermore,&nbsp;children with XLA should not be given live viral vaccines. For example, they should&nbsp;be given inactivated polio vaccine (IPV) rather than the oral polio vaccine. The siblings of children with XLA should also be given inactivated polio vaccine (IPV) rather than oral polio vaccine in order to avoid infecting their affected sibling with live virus.[4038]","dateModified":"2011-08-03T11:46:00","resourceClassificationName":"Treatment","references":[{"referenceId":4038,"authors":"Mary Ellen Conley, Vanessa C Howard","articleTitle":"X-Linked Agammaglobulinemia","bookWebsiteJournalTitle":"GeneReviews","date":"July 30, 2009","url":"http://www.ncbi.nlm.nih.gov/books/NBK1453/","dateAccessed":"2011-08-03T00:00:00"}]},{"questionId":5035,"questionText":"What can I do if intravenous infusion of gammaglobulin is not available where I live?","answerText":"Although gammaglobulin is the treatment of choice for XLA, there may be alternatives to intravenous gammaglobulin. In the last few years, an increasing number of people have been receiving gammaglobulin treatment&nbsp;by weekly <a href=\"http://www.cc.nih.gov/ccc/patient_education/pepubs/subq.pdf\" target=_blank>subcutaneous injections</a>.[4038] This is an injection&nbsp;(like a shot) given in the fatty layer of tissue just under the skin.&nbsp;Injection may also&nbsp;have the advantage of providing IgG levels that are relatively constant, compared with the highs and lows of levels that may occur with IV therapy. Another advantage is that injections may be given at home. Disadvantages of having injections may include&nbsp;discomfort where the injections are given, and the potential lack of medical supervision by doctors (because coming to the hospital for infusions may no longer be necessary). Fresh frozen plasma (FFP), used in blood transfusions, has been used in the past but carries the major risk of potential transmission of infectious diseases.[4039]<br><br>If you do not have access to gammaglobulin or other&nbsp;treatments where you live, it is recommended that you contact the various support groups for XLA that we have listed on our Web site. You can see the contact information for these&nbsp;support groups by <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/1033/Xlinked_agammaglobulinemia.aspx/Panel4#Resources\" target=_blank>clicking here</a>.&nbsp;These groups may be able to help you either&nbsp;locate&nbsp;a physician or treatment center&nbsp;that is accessible, or provide you with information about how to obtain gammaglobulin or other treatments for XLA.","dateModified":"2011-08-03T12:40:00","references":[{"referenceId":4038,"authors":"Mary Ellen Conley, Vanessa C Howard","articleTitle":"X-Linked Agammaglobulinemia","bookWebsiteJournalTitle":"GeneReviews","date":"July 30, 2009","url":"http://www.ncbi.nlm.nih.gov/books/NBK1453/","dateAccessed":"2011-08-03T00:00:00"},{"referenceId":4039,"authors":"Terry W Chin","articleTitle":"Pediatric Bruton Agammaglobulinemia ","bookWebsiteJournalTitle":"eMedicine","date":"September 28, 2010","url":"http://emedicine.medscape.com/article/885625-overview","dateAccessed":"2011-08-03T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":11840,"phenoTypeName":"Abnormality of the tonsils","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9218,"phenoTypeName":"Agammaglobulinemia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13420,"phenoTypeName":"Chronic diarrhea","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11326,"phenoTypeName":"Chronic otitis media","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5616,"phenoTypeName":"Conjunctivitis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4081,"phenoTypeName":"Failure to thrive","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9762,"phenoTypeName":"Glossoptosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10673,"phenoTypeName":"Immunodeficiency","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11850,"phenoTypeName":"Recurrent cutaneous abscess formation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10186,"phenoTypeName":"Recurrent pneumonia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3605,"phenoTypeName":"Short stature","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9832,"phenoTypeName":"Sinusitis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8270,"phenoTypeName":"Skin rash","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":967,"phenoTypeName":"Skin ulcer","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5670,"phenoTypeName":"Arthritis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":147,"phenoTypeName":"Cellulitis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4309,"phenoTypeName":"Hypocalcemia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8738,"phenoTypeName":"Meningitis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15514,"phenoTypeName":"Neutropenia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11337,"phenoTypeName":"Sensorineural hearing impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":1873,"phenoTypeName":"Sepsis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4756,"phenoTypeName":"Alopecia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15539,"phenoTypeName":"Anemia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4355,"phenoTypeName":"Autoimmunity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2701,"phenoTypeName":"Hepatitis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9285,"phenoTypeName":"Hypopigmented skin patches","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13413,"phenoTypeName":"Malabsorption","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13290,"phenoTypeName":"Neoplasm","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10592,"phenoTypeName":"Osteomyelitis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15512,"phenoTypeName":"Thrombocytopenia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8982,"phenoTypeName":"Cor pulmonale","percentRanges":"-"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","percentRanges":"-"},{"phenoTypeId":13401,"phenoTypeName":"Diarrhea","percentRanges":"-"},{"phenoTypeId":5158,"phenoTypeName":"Encephalitis","percentRanges":"-"},{"phenoTypeId":5268,"phenoTypeName":"Enteroviral dermatomyositis syndrome","percentRanges":"-"},{"phenoTypeId":5703,"phenoTypeName":"Enteroviral hepatitis","percentRanges":"-"},{"phenoTypeId":9,"phenoTypeName":"Epididymitis","percentRanges":"-"},{"phenoTypeId":11303,"phenoTypeName":"Hearing impairment","percentRanges":"-"},{"phenoTypeId":10684,"phenoTypeName":"Lymph node hypoplasia","percentRanges":"-"},{"phenoTypeId":11325,"phenoTypeName":"Otitis media","percentRanges":"-"},{"phenoTypeId":13723,"phenoTypeName":"Pneumonia","percentRanges":"-"},{"phenoTypeId":6360,"phenoTypeName":"Prostatitis","percentRanges":"-"},{"phenoTypeId":8279,"phenoTypeName":"Pyoderma","percentRanges":"-"},{"phenoTypeId":6542,"phenoTypeName":"Recurrent urinary tract infections","percentRanges":"-"},{"phenoTypeId":14549,"phenoTypeName":"Septic arthritis","percentRanges":"-"},{"phenoTypeId":5707,"phenoTypeName":"X-linked recessive inheritance","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"X-linked_agammaglobulinemia"}